OOIR: Observatory of International Research

Papers

(The H4-Index of Biomarker Research is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study	175
Development and validation of predictive models combining cell-Free DNA motifs and protein biomarkers for early detection of esophageal squamous cell carcinoma and precancerous lesion	145
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma	125
Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting	122
The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model	122
Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate cancer metastasis through the RACK1 signaling axis	114
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients	114
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer	110
CardioAtlas: deciphering the single-cell transcriptome landscape in cardiovascular tissues and diseases	109
Mitochondrial transfer in hematological malignancies	99
Unraveling the immune microenvironment in primary CNS lymphoma	96
Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma	96
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes	89
Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases	88
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors	86
Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology	84
The overlooked trio: sleep duration, sampling time and physical exercise alter levels of olink-assessed blood biomarkers of cardiovascular risk	84
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma	83
Dynamic changes of bone microarchitecture and volumetric mineral density assessed by HR-pQCT in patients with cervical cancer after concurrent chemoradiotherapy: a prospective study	83
The molecular landscape of the C1498 murine acute myeloid leukemia cell line	83
p53 biology and reactivation for improved therapy in MDS and AML	82
Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer	80
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy	80
tRNA modifications in cancer: from molecular mechanisms to clinical translation	79
Emerging roles of circular RNAs and enhancer RNAs: new insights into the development and management of neurodegenerative disorders	77

miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC	74
Multi-omics profiling reveals intrathymic triggers and novel biomarkers in thymoma-associated myasthenia gravis	71
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells	70
Decoding the microbiome-immune crosstalk in cancer: from mechanisms to therapeutic translation	66
The formation and function of tertiary lymphoid structures	66
Unveiling the potential of CLL-1: a promising target for AML therapy	65
Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy	63
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends	60
Monocyte-macrophages modulate intestinal homeostasis in inflammatory bowel disease	57
Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus	56
Nanoparticles-enhanced CAR-T cell therapy: current advances and future directions	56
Correction: Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities	55
Dysregulation of plasma circulating microRNAs in all-cause and cause-specific cancers: the Rotterdam Study	54
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics	53
Multiple regulatory events contribute to a widespread circular RNA downregulation in precancer and early stage of colorectal cancer development	52
The role and metabolic adaptations of neutrophils in premetastatic niches	52
STAT3–mediated up-regulation of DAB2 via SRC-YAP1 signaling axis promotes Helicobacter pylori-driven gastric tumorigenesis	51
RUNX1 promotes angiogenesis in colorectal cancer by regulating the crosstalk between tumor cells and tumor associated macrophages	50
Proteomic and histopathologic profiling reveal molecular features and clinical biomarkers of coronary atherosclerosis	50
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients	50
The role of BATF in immune cell differentiation and autoimmune diseases	49
Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer	48
The involvement of krüppel-like transcription factor 2 in megakaryocytic differentiation induction by phorbol 12-myrestrat 13-acetate	48
Glycochenodeoxycholic acid promotes hepatocarcinogenesis by inducing hepatic progenitor cell differentiation into cancer-associated fibroblasts via sphingosine-1-phosphate receptor 2 signalling	48